Dr. Baumgartner joined the Ardea Biosciences team in August 2011 as Executive Medical Director with medical responsibilities for the initiation and execution of phase 3 trials with lesinurad in gout. He currently serves as Vice President Medical Affairs, promoted in 2014, responsible for the medical aspects of Global Medical Affairs and Global Marketing activities for Ardea’s gout portfolio. Previous to his current role, Dr. Baumgartner was Vice President, Clinical Research and Development where he led clinical operations, data management and biostatistics. Prior to joining Ardea, Dr. Baumgartner worked for Amgen where he led the Enbrel rheumatology programs and worked in clinical development on pipeline biologics in inflammation. He received his MD degree from the University of Washington, and is board certified in internal medicine and rheumatology. He practiced rheumatology for over 20 years, and was involved extensively in clinical research. He has authored or co-authored over 50 manuscripts and abstracts.